1-10 of 10
Morris A. Blajchman
Close
Sort by
Journal Articles

Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention

Eleftherios C. Vamvakas, Morris A. Blajchman
Journal: Blood
Blood (2009) 113 (15): 3406–3417.
https://doi.org/10.1182/blood-2008-10-167643
Published: 2009
Journal Articles

The Pathogen Inactivation of Platelets: Studies of the Possible Mechanisms of the Platelet Dysfunction Seen Following Photochemical Treatment.

Adam D. Pyke, BA, MSc, Morris A. Blajchman, MD, FRCP(C)
Journal: Blood
Blood (2006) 108 (11): 581.
https://doi.org/10.1182/blood.V108.11.581.581
Published: 2006
Journal Articles

Human Factor VIIai(K62E) Is a More Effective Inhibitor of Coagulation Than Wild-Type FVIIai.

Bryan J. Clarke, PhD, Sampath Sridhara, Ph.D, Morris A. Blajchman, MD
Journal: Blood
Blood (2005) 106 (11): 1949.
https://doi.org/10.1182/blood.V106.11.1949.1949
Published: 2005
Journal Articles

A Multicenter, Randomized, Controlled Clinical Pilot Trial of the Feasibility of an Intensive RBC Transfusion Policy for Patients with Acute Leukemia Treated with Induction Chemotherapy or Stem Cell Transplant.

Kathryn E. Webert, MD, Richard J. Cook, PhD, Morris A. Blajchman, MD, Stephen Couban, MD, David M. Sutton, MD, Jeffrey H. Lipton, MD, Julie Carruthers, Joseph Brandwein, MD, Nancy M. Heddle, MSc, FCMLS(D)
Journal: Blood
Blood (2005) 106 (11): 4183.
https://doi.org/10.1182/blood.V106.11.4183.4183
Published: 2005
Journal Articles

The Use of Aprotinin to Reduce Transfusion Requirements in Children Undergoing Cardiac Surgery: A Meta-Analysis.

Donald M. Arnold, MD, FRCPC, Dean A. Fergusson, MHA, PhD, Anthony K. Chan, MBBS, FRCPC, Richard J. Cook, PhD, Graeme A. Fraser, MD, BSc, FRCPC, Wendy Lim, MD, FRCPS, Nancy M. Heddle, MSc, FCMLS(D), Morris A. Blajchman, MD, FRCPC, Deborah J. Cook, MD, MSc, FRCPC
Journal: Blood
Blood (2004) 104 (11): 2718.
https://doi.org/10.1182/blood.V104.11.2718.2718
Published: 2004
Journal Articles

An Animal Model Suitable for Predicting In Vivo Behavior of Platelets in Humans: A Tool for New Product Development.

Morris A. Blajchman, Junzhi Li, Myron Kulczycky, Zofia Woskowska, Henry Pieters, Jan Roodt, Philip Badenhorst, Robert Crookes, Anthon Heyns, Raymond Goodrich
Journal: Blood
Blood (2004) 104 (11): 3628.
https://doi.org/10.1182/blood.V104.11.3628.3628
Published: 2004
Journal Articles

The Mechanism of Transfusion-Related Immunomodulation Is Related to the Transfusion of Dendritic Cells Expressing the CD200 (OX-2) Tolerance Signal and Alloantigen: Evidence from a Murine Tumor Model.

Morris A. Blajchman, MD, FRCP(C), Reginald M. Gorczynski, David A. Clark, MD
Journal: Blood
Blood (2004) 104 (11): 831.
https://doi.org/10.1182/blood.V104.11.831.831
Published: 2004
Journal Articles

Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction?

Clinical Trials & Observations
Eleftherios C. Vamvakas, Morris A. Blajchman
Journal: Blood
Blood (2001) 97 (5): 1180–1195.
https://doi.org/10.1182/blood.V97.5.1180
Published: 2001
Journal Articles

o -Raffinose cross-linked hemoglobin improves the hemostatic defect associated with anemia and thrombocytopenia in rabbits

David H. Lee, Leslie Bardossy, Nichole Peterson, Morris A. Blajchman
Journal: Blood
Blood (2000) 96 (10): 3630–3636.
https://doi.org/10.1182/blood.V96.10.3630
Published: 2000
Journal Articles

Factor VII Deficiency Caused by a Structural Variant N57D of the First Epidermal Growth Factor Domain

Blair J.N. Leonard, Qi Chen, Morris A. Blajchman, Frederick A. Ofosu, Sampath Sridhara, Daniel Yang, Bryan J. Clarke
Journal: Blood
Blood (1998) 91 (1): 142–148.
https://doi.org/10.1182/blood.V91.1.142
Published: 1998